| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1029157397 |
| P356 | DOI | 10.1038/ONC.2012.378 |
| P953 | full work available at URL | https://doi.org/10.1038/onc.2012.378 |
| https://europepmc.org/articles/PMC3670968 | ||
| https://europepmc.org/articles/PMC3670968?pdf=render | ||
| https://www.nature.com/articles/onc2012378 | ||
| https://www.nature.com/articles/onc2012378.pdf | ||
| P932 | PMC publication ID | 3670968 |
| P698 | PubMed publication ID | 22945653 |
| P5875 | ResearchGate publication ID | 230791159 |
| P50 | author | Peter K. Sorger | Q42127905 |
| Taran Gujral | Q79354837 | ||
| P2093 | author name string | M. Chan | |
| P. E. Schwartz | |||
| G. MacBeath | |||
| A. Finski | |||
| R. L. Karp | |||
| P2860 | cites work | Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors | Q38485846 |
| Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. | Q38516613 | ||
| Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown | Q39452760 | ||
| Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks | Q39528185 | ||
| Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer | Q39634782 | ||
| AXL is a potential target for therapeutic intervention in breast cancer progression. | Q40002526 | ||
| A novel activating role of SRC and STAT3 on HGF transcription in human breast cancer cells | Q40060829 | ||
| Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. | Q40218927 | ||
| Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells | Q40220260 | ||
| State-based discovery: a multidimensional screen for small-molecule modulators of EGF signaling | Q40228748 | ||
| Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells | Q40344963 | ||
| Detection of multiple cytokines by protein arrays from cell lysate and tissue lysate | Q40597146 | ||
| Gas6 anti-apoptotic signaling requires NF-kappa B activation. | Q40796453 | ||
| R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer | Q43166849 | ||
| GNCPro: Navigate Human Genes and Relationships Through Net-Walking | Q44489870 | ||
| Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm | Q44529239 | ||
| C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu | Q45083973 | ||
| A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells | Q45345816 | ||
| Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays | Q51943602 | ||
| Statistical Methods for Identifying Differentially Expressed Genes in DNA Microarrays | Q58618312 | ||
| Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 | ||
| MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | Q24646295 | ||
| Prolinks: a database of protein functional linkages derived from coevolution | Q24801555 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Met, metastasis, motility and more | Q28235183 | ||
| Cancer genes and the pathways they control | Q28275089 | ||
| A combined algorithm for genome-wide prediction of protein function | Q29615998 | ||
| Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays | Q30449558 | ||
| Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy | Q30494709 | ||
| Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma | Q30965944 | ||
| Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front | Q30989699 | ||
| Signal pathway profiling of prostate cancer using reverse phase protein arrays | Q31021936 | ||
| Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision | Q31080215 | ||
| Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. | Q33597322 | ||
| Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival | Q33667156 | ||
| Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer | Q33874421 | ||
| A hierarchical unsupervised growing neural network for clustering gene expression patterns | Q33936864 | ||
| Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade | Q34008159 | ||
| Evidence that fold-change, and not absolute level, of beta-catenin dictates Wnt signaling | Q34087711 | ||
| Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates | Q34088416 | ||
| Principles and strategies for developing network models in cancer | Q34171479 | ||
| Lysate microarrays enable high-throughput, quantitative investigations of cellular signaling | Q34751674 | ||
| Gab1 is required for cell cycle transition, cell proliferation, and transformation induced by an oncogenic met receptor. | Q35010265 | ||
| A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers | Q35049524 | ||
| Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer | Q35206302 | ||
| Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence | Q36030339 | ||
| Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA | Q36054278 | ||
| A dual array-based approach to assess the abundance and posttranslational modification state of signaling proteins | Q36300039 | ||
| Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases | Q36493822 | ||
| Bead-based microfluidic immunoassays: the next generation | Q36542213 | ||
| Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. | Q36950451 | ||
| Cytokine-induced signaling networks prioritize dynamic range over signal strength | Q37081858 | ||
| Functional proteomics to dissect tyrosine kinase signalling pathways in cancer | Q37780948 | ||
| A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors | Q38304282 | ||
| P433 | issue | 29 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 3470-3476 | |
| P577 | publication date | 2012-09-03 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays | |
| P478 | volume | 32 |
| Q89686521 | (-)-Epigallocatechin gallate inhibits stemness and tumourigenicity stimulated by AXL receptor tyrosine kinase in human lung cancer cells |
| Q24307454 | A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis |
| Q90148023 | AXL as a Target in Breast Cancer Therapy |
| Q34619118 | Axl as a mediator of cellular growth and survival |
| Q100517557 | Bispecific Antibodies for Triple Negative Breast Cancer |
| Q38890784 | Cell signaling regulation by protein phosphorylation: a multivariate, heterogeneous, and context-dependent process |
| Q38900933 | Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer |
| Q41881663 | Combined treatment with MET inhibitors and other therapies in lung cancer |
| Q34361161 | Complexity of receptor tyrosine kinase signal processing |
| Q36111215 | Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer |
| Q55040593 | Current applications of antibody microarrays. |
| Q36134032 | Evaluation of Protein Profiles From Treated Xenograft Tumor Models Identifies an Antibody Panel for Formalin-fixed and Paraffin-embedded (FFPE) Tissue Analysis by Reverse Phase Protein Arrays (RPPA) |
| Q35675442 | Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches. |
| Q97521808 | Ex vivo assessment of targeted therapies in a rare metastatic epithelial-myoepithelial carcinoma |
| Q57117017 | Genetic disruption of calpain-1 and calpain-2 attenuates tumorigenesis in mouse models of HER2+ breast cancer and sensitizes cancer cells to doxorubicin and lapatinib |
| Q37221907 | Global Conservation of Protein Status between Cell Lines and Xenografts |
| Q36525420 | Glucose starvation induces mutation and lineage-dependent adaptive responses in a large collection of cancer cell lines |
| Q39389369 | Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. |
| Q47842853 | Identification of cellular responses to low-dose radiation by the profiling of phosphorylated proteins in human B-lymphoblast IM-9 cells |
| Q37698227 | Implications of functional proteomics in breast cancer |
| Q39157476 | Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies |
| Q37745358 | Molecular insights of Gas6/TAM in cancer development and therapy. |
| Q47593253 | Protein Arrays III: Reverse-Phase Protein Arrays |
| Q38673773 | Protein arrays for biomarker discovery in lupus |
| Q38212502 | Proteomic analysis of tissue samples in translational breast cancer research. |
| Q34062012 | Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas |
| Q42998414 | Quantitative analysis of signaling networks across differentially embedded tumors highlights interpatient heterogeneity in human glioblastoma |
| Q34704781 | Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors |
| Q41688304 | Reverse Phase Protein Arrays for Compound Profiling |
| Q36519831 | Reverse phase protein arrays: mapping the path towards personalized medicine. |
| Q39377837 | Signaling pathway profiling using reverse-phase protein array and its clinical applications. |
| Q38894416 | Systematic analysis of BRAF(V600E) melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis |
| Q38835745 | Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma |
| Q51146366 | The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer. |
| Q89121009 | The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer |
| Q35200483 | ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients. |
| Q35897588 | miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation |
Search more.